JP2024511057A - Ｋｖ７チャネル開口剤のプロドラッグ - Google Patents

Ｋｖ７チャネル開口剤のプロドラッグ Download PDF

Info

Publication number
JP2024511057A
JP2024511057A JP2023557407A JP2023557407A JP2024511057A JP 2024511057 A JP2024511057 A JP 2024511057A JP 2023557407 A JP2023557407 A JP 2023557407A JP 2023557407 A JP2023557407 A JP 2023557407A JP 2024511057 A JP2024511057 A JP 2024511057A
Authority
JP
Japan
Prior art keywords
depression
disease
disorder
disorders
dystonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511057A5 (https=
Inventor
クリストファー エス． クリーン，
エドワード ジー． ブラウン，
Original Assignee
ジザジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジザジェン， インコーポレイテッド filed Critical ジザジェン， インコーポレイテッド
Publication of JP2024511057A publication Critical patent/JP2024511057A/ja
Publication of JP2024511057A5 publication Critical patent/JP2024511057A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
JP2023557407A 2021-03-19 2022-03-20 Ｋｖ７チャネル開口剤のプロドラッグ Pending JP2024511057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163470P 2021-03-19 2021-03-19
US63/163,470 2021-03-19
PCT/US2022/021059 WO2022198116A1 (en) 2021-03-19 2022-03-20 Prodrugs of kv7 channel openers

Publications (2)

Publication Number Publication Date
JP2024511057A true JP2024511057A (ja) 2024-03-12
JP2024511057A5 JP2024511057A5 (https=) 2025-02-10

Family

ID=83321210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023557407A Pending JP2024511057A (ja) 2021-03-19 2022-03-20 Ｋｖ７チャネル開口剤のプロドラッグ
JP2023557288A Pending JP2024511997A (ja) 2021-03-19 2022-03-20 Ｋｖ７チャネル開口剤のプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023557288A Pending JP2024511997A (ja) 2021-03-19 2022-03-20 Ｋｖ７チャネル開口剤のプロドラッグ

Country Status (11)

Country Link
US (3) US20240300894A1 (https=)
EP (3) EP4308545A4 (https=)
JP (2) JP2024511057A (https=)
KR (2) KR20230159506A (https=)
CN (3) CN117295711A (https=)
AU (3) AU2022240779A1 (https=)
BR (2) BR112023019074A2 (https=)
CA (3) CA3214270A1 (https=)
IL (2) IL306005A (https=)
MX (2) MX2023010976A (https=)
WO (3) WO2022198116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860727A (zh) * 2022-09-26 2024-04-12 江苏海洋大学 一种用于预防或治疗疼痛的药物组合物
CN118553447B (zh) * 2024-07-30 2024-11-08 四川大学华西医院 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004115450A (ja) * 2002-09-27 2004-04-15 Tanabe Seiyaku Co Ltd 医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
TWI453013B (zh) * 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
GB0813403D0 (en) * 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
WO2013179298A2 (en) * 2012-04-23 2013-12-05 Cadila Healthcare Limited A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
US10526280B2 (en) * 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
MX2018015251A (es) * 2016-06-10 2019-04-25 Scifluor Life Sciences Inc Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
AU2019335070A1 (en) * 2018-09-06 2021-05-13 Ian Cooke Method of treating a sleep breathing disorder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004115450A (ja) * 2002-09-27 2004-04-15 Tanabe Seiyaku Co Ltd 医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CNS DRUG REVIEWS, vol. Vo. 11, No. 1, JPN6025048123, 7 June 2006 (2006-06-07), pages 1 - 20, ISSN: 0005738321 *
MOLECULES, vol. 13, no. 3, JPN6025048122, 2008, pages 519 - 547, ISSN: 0005738322 *

Also Published As

Publication number Publication date
CN117295711A (zh) 2023-12-26
IL306004A (en) 2023-11-01
US20240228434A1 (en) 2024-07-11
CA3214270A1 (en) 2022-09-22
AU2022237675A1 (en) 2023-10-12
BR112023019077A2 (pt) 2023-12-05
IL306005A (en) 2023-11-01
US20240300894A1 (en) 2024-09-12
JP2024511997A (ja) 2024-03-18
BR112023019074A2 (pt) 2023-12-05
MX2023010978A (es) 2023-12-07
EP4308544A1 (en) 2024-01-24
WO2022198116A1 (en) 2022-09-22
KR20230159506A (ko) 2023-11-21
WO2022198116A9 (en) 2022-10-27
MX2023010976A (es) 2023-12-07
AU2022240779A1 (en) 2023-10-12
CA3214084A1 (en) 2022-09-22
CA3214305A1 (en) 2022-09-22
AU2022239618A1 (en) 2023-10-05
KR20230159531A (ko) 2023-11-21
CN117355503A (zh) 2024-01-05
EP4308543A4 (en) 2025-04-30
EP4308544A4 (en) 2025-04-30
WO2022198115A1 (en) 2022-09-22
EP4308543A1 (en) 2024-01-24
EP4308545A1 (en) 2024-01-24
EP4308545A4 (en) 2025-04-30
CN117321031A (zh) 2023-12-29
WO2022198116A8 (en) 2023-11-09
WO2022198114A1 (en) 2022-09-22
US20240208896A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
JP6873433B2 (ja) タンパク質分解のイミド系修飾因子および関連の使用方法
JP2024511057A (ja) Ｋｖ７チャネル開口剤のプロドラッグ
JP2022521605A (ja) 統合的ストレス応答経路の阻害剤
AU2015207867A1 (en) Compounds and methods for the treatment of pain and other diseases
US11098013B2 (en) Small molecule N-(α-peroxy) carbazole compounds and methods of use
KR20020038947A (ko) 씨엔에스 질환에 대한 카보닐아미노 유도체의 용도
EP3455208B1 (en) Small molecule n-(alpha-peroxy) indole compounds and methods of use
US9505743B2 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
WO2024178425A1 (en) Hydroxyalkyl and methoxyalkyl tryptamines
KR100267707B1 (ko) Nmda 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산 유도체
JP2025539698A (ja) 新規シアノピリジンｋｈｋ阻害剤化合物
KR19990038717A (ko) 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1ｈ)-온 유도체 및 그들의 제조방법
KR19990071254A (ko) Nmda 수용체 길항제로 작용하는 4-(3-치환-2-옥소 및 2-티옥소-1,3-옥사졸리딘-5-일메톡시)-퀴놀린-2-카복실산 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250131

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260224